Browse > Article

Radiosynthesis of $[^{11}C]6-OH-BTA-1$ in Different Media and Confirmation of Reaction By-products.  

Lee, Hak-Jeong (Department of Nuclear Medicine, Seoul National University College of Medicine)
Jeong, Jae-Min (Department of Nuclear Medicine, Seoul National University College of Medicine)
Lee, Yun-Sang (Department of Nuclear Medicine, Seoul National University College of Medicine)
Kim, Hyung-Woo (Department of Nuclear Medicine, Seoul National University College of Medicine)
Lee, Eun-Kyoung (Clinical Research Institute, Seoul National University Hospital)
Lee, Dong-Soo (Department of Nuclear Medicine, Seoul National University College of Medicine)
Chung, June-Key (Department of Nuclear Medicine, Seoul National University College of Medicine)
Lee, Myung-Chul (Department of Nuclear Medicine, Seoul National University College of Medicine)
Publication Information
Nuclear Medicine and Molecular Imaging / v.41, no.3, 2007 , pp. 241-246 More about this Journal
Abstract
Purpose: $[^{11}C]6-OH-BTA-1$ ([N-methyl-$^{11}C$]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole, 1), a -amyloid imaging agent for the diagnosis of Alzheimer's disease in PET, can be labeled with higher yield by a simple loop method. During the synthesis of $[^{11}C]1$, we found the formation of by-products in various solvents, e.g., methylethylketone (MEK), cyclohexanone (CHO), diethylketone (DEK), and dimethylformamide (DMF). Materials and Methods: In Automated radiosynthesis module, 1 mg of 4-aminophenyl-6-hydroxybenzothiazole (4) in 100 l of each solvent was reacted with $[^{11}C]methyl$ triflate in HPLC loop at room temperature (RT). The reaction mixture was separated by semi-preparative HPLC. Aliquots eluted at 14.4, 16.3 and 17.6 min were collected and analyzed by analytical HPLC and LC/MS spectrometer. Results: The labeling efficiencies of $[^{11}C]1$ were $86.0{\pm}5.5%$, $59.7{\pm}2.4%$, $29.9{\pm}1.8%$, and $7.6{\pm}0.5%$ in MEK, CHO, DEK and DMF, respectively. The LC/MS spectra of three products eluted at 14.4, 16.3 and 17.6 mins showed m/z peaks at 257.3 (M+1), 257.3 (M+1) and 271.3 (M+1), respectively, indicating their structures as 1, 2-(4'-aminophenyl)-6-methoxybenzothiazole (2) and by-product (3), respectively. Ratios of labeling efficiencies for the three products $([^{11}C]1:[^{11}C]2:[^{11}C]3)$ were $86.0{\pm}5.5%:5.0{\pm}3.4%:1.5{\pm}1.3%$ in MEK, $59.7{\pm}2.4%:4.7{\pm}3.2%:1.3{\pm}0.5%$ in CHO, $9.9{\pm}1.8%:2.0{\pm}0.7%:0.3{\pm}0.1%$ in DEK and $7.6{\pm}0.5%:0.0%:0.0%$ in DMF, respectively. Conclusion: The labeling efficiency of $[^{11}C]1$ was the highest when MEK was used as a reaction solvent. As results of mass spectrometry, 1 and 2 were conformed. 3 was presumed.
Keywords
Alzheimer's disease; PIB; PET; by-product; $[^{11}C]methyl triflate$; $[^{11}C]6-OH-BTA-1$; loop method; ${\beta}-amyloid plaque$;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Schenk DB, Seubert P, Lieberburg I, Wallace J. {beta}-Peptide Immunization: A Possible New Treatment for Alzheimer Disease. Arch Neurol 2000;57:934-6   DOI   ScienceOn
2 Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, et al. Novel Therapeutic Approach for the Treatment of Alzheimer's Disease by Peripheral Administration of Agents with an Affinity to beta -Amyloid. J Neurosci 2003;23:29-33   DOI
3 Klunk WE, Wang Y, Huang G-f, Debnath ML, Holt DP, Mathis CA. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 2001;69: 1471-84   DOI   ScienceOn
4 Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005;25:10598-606   DOI   ScienceOn
5 Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005;25:1528-47   DOI   ScienceOn
6 Choe YS. Radiolabeling Methods Used for Preparation of Molecular Probes. Korean J Nucl Med 2004;38:121-30
7 Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86   DOI
8 Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 2002;12:295-8   DOI   ScienceOn
9 Wilson AA, Garcia A, Chestakova A, Kung H, Houle S. A rapid one-step radiosynthesis of the b-amyloid imaging radiotracer N-methyl-[$^{11}$C]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole ([$^{11}$C]-6-OH-BTA-1). J Labelled Cpd Radiopharm 2004;47:679-82   DOI   ScienceOn
10 Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and Evaluation of 11C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents. J Med Chem 2003;46:2740-54   DOI   ScienceOn
11 Klunk WE, Abraham DJ. Filamentous proteins in Alzheimer's disease: new insights through molecular biology. Psych Dev 1988;6:121-52
12 Mathis CA, Holt DP, Wang Y, Huang GF, Debmath ML, Klunk WE. Lipophilic $^{11}$C-labelled thioflavin-T analogues for imaging amyloid plaques in Alzheimer's disease. J Labelled Compd Radiopharm 2001;44:S26-S8   DOI   ScienceOn
13 Bacskai BJ, Hickey GA, Skoch J, Kajdasz ST, Wang Y, Huang GF, et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci USA 2003;100:12462-7   DOI   ScienceOn
14 Schenk DB, Rydel RE, May P, Little S, Panetta J, Lieberburg I, et al. Therapeutic approaches related to amyloid-beta peptide and Alzheimer's disease. J Med Chem 1995;38:4141-54   DOI   ScienceOn
15 Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19   DOI   ScienceOn
16 Solbach C, Uebele M, Reischl G, Machulla HJ. Efficient radiosynthesis of carbon-11 labelled uncharged Thioflavin T derivatives using [11C]methyl triflate for [beta]-amyloid imaging in Alzheimer's Disease with PET. Appl Radiat Isot 2005;62:591-5   DOI   ScienceOn
17 Iwata R, Pascali C, Bogni A, Miyake Y, Yanai K, Ido T. A simple loop method for the automated preparation of [$^{11}$C]raclopride from [$^{11}$C]methyl triflate. Appl Radiat Isot 2001;55:17-22   DOI   ScienceOn
18 Olson RE, Copeland RA, Seiffert D. Progress towards testing the amyloid hypothesis: inhibitors of APP processing. Curr Op Drug Disc Dev 2001;4:390-401
19 Holtzman DM, Bales KR, Paul SM, DeMattos RB. A[beta] immunization and anti-A[beta] antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. Advan Drug Delivery Rev 2002;54:1603-13   DOI   ScienceOn
20 Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59   DOI
21 Jewett DM. A simple synthesis of [$^{11}$C]methyl triflate. Appl Radiat Isot 1992;43:1383-5   DOI   ScienceOn
22 DeKosky ST, Marek K. Looking Backward to Move Forward: Early Detection of Neurodegenerative Disorders. Science 2003;302: 830-4   DOI   ScienceOn